I. White

发表

α-Hydroxytamoxifen, a genotoxic metabolite of tamoxifen in the rat: identification and quantification in vivo and in vitro

B. K. Park, J. Maggs, D. Boocock, 1999 .

Absence of uterine tumours in CD-1 mice treated neonatally with subcutaneous tamoxifen or 4-hydroxyoestradiol.

J. Styles, P. Greaves, R. Edwards, 2007, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

Chemoprevention of Breast Cancer by Tamoxifen: Risks and Opportunities

J. Styles, K. Brown, P. Carthew, 2000, Toxicology letters.

Identification of human CYP forms involved in the activation of tamoxifen and irreversible binding to DNA.

K. Turteltaub, E. Sánchez, D. Boocock, 2002, Carcinogenesis.

Differing transcriptional responses to pulsed or continuous estradiol exposure in human umbilical vein endothelial cells

Suzanne M Johnson, J. Thompson, Jin Li, 2008, The Journal of Steroid Biochemistry and Molecular Biology.

Techniques: the application of accelerator mass spectrometry to pharmacology and toxicology.

K. Brown, I. White, 2004, Trends in pharmacological sciences.

Ishikawa cells exhibit differential gene expression profiles in response to oestradiol or 4-hydroxytamoxifen.

Suzanne M Johnson, J. Styles, I. White, 2007, Endocrine-related cancer.

Changes in transcription profile and cytoskeleton morphology in pelvic ligament fibroblasts in response to stretch: the effects of estradiol and levormeloxifene.

J. Thompson, J. Styles, Jin Li, 2007, Molecular human reproduction.

Comparison of the effect of oestradiol, tamoxifen and raloxifene on nerve growth factor-alpha expression in specific neonatal mouse uterine cell types using laser capture microdissection.

P. Greaves, R. Edwards, A. Green, 2003, Journal of molecular endocrinology.

Influence of oestradiol and tamoxifen on oestrogen receptors-α and -β protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells

Suzanne M. Johnson, C. Guérin, C J Guerin, 2005 .

Mutational specificity: Mutational spectra of tamoxifen‐induced mutations in the livers of lacl transgenic rats

J. Styles, K. Lilley, R. Davies, 1996 .

Applications of accelerator mass spectrometry for pharmacological and toxicological research.

Karen Brown, K. Brown, Elaine M Tompkins, 2006, Mass spectrometry reviews.

Experimental adenomyosis.

P. Greaves, I. White, 2006, Best practice & research. Clinical obstetrics & gynaecology.

Co-chromatography of a tamoxifen epoxide-deoxyguanylic acid adduct with a major DNA adduct formed in the livers of tamoxifen-treated rats.

D. Phillips, A. Hewer, I. White, 1994, Carcinogenesis.

Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells.

S. Venitt, D. Phillips, A. Hewer, 1992, Carcinogenesis.

Neonatal tamoxifen treatment of mice leads to adenomyosis but not uterine cancer.

J. Styles, Andrew G Smith, T. Gant, 2005, Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie.

SCCP/SCHER/SCENIHR preliminary report on: the Use of the Threshold of Toxicological Concern (TTC) Approach for the Safety Assessment of Chemical Substances

Marco Vighi, Konrad Rydzynski, Vera Rogiers, 2008 .

Further characterization of the DNA adducts formed in rat liver after the administration of tamoxifen, N-desmethyltamoxifen or N, N-didesmethyltamoxifen.

I. White, E. Martin, R. Heydon, 1999, Carcinogenesis.